Short Interest in Cardlytics Inc (NASDAQ:CDLX) Declines By 15.3%

Share on StockTwits

Cardlytics Inc (NASDAQ:CDLX) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 3,071,500 shares, a decline of 15.3% from the July 31st total of 3,627,100 shares. Based on an average trading volume of 359,400 shares, the short-interest ratio is currently 8.5 days. Approximately 19.0% of the company’s stock are short sold.

In other Cardlytics news, CEO Scott D. Grimes sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $23.76, for a total value of $95,040.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bryce Youngren sold 135,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $34.99, for a total value of $4,723,650.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,354,392 shares of company stock worth $72,349,708 over the last three months. 21.90% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. River & Mercantile Asset Management LLP bought a new position in Cardlytics during the 2nd quarter worth $1,063,000. Royal Bank of Canada grew its stake in Cardlytics by 166.5% during the 2nd quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock worth $276,000 after buying an additional 6,649 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Cardlytics during the 2nd quarter worth $277,000. Morgan Stanley grew its stake in Cardlytics by 760.1% during the 2nd quarter. Morgan Stanley now owns 13,177 shares of the company’s stock worth $342,000 after buying an additional 11,645 shares during the last quarter. Finally, UBS Oconnor LLC grew its stake in Cardlytics by 12.1% during the 2nd quarter. UBS Oconnor LLC now owns 344,354 shares of the company’s stock worth $8,946,000 after buying an additional 37,153 shares during the last quarter. Hedge funds and other institutional investors own 85.01% of the company’s stock.

CDLX traded down $1.98 during trading on Friday, reaching $35.49. 15,845 shares of the company were exchanged, compared to its average volume of 532,278. The stock has a market cap of $855.44 million, a P/E ratio of -16.37 and a beta of 1.55. The firm has a 50 day moving average of $32.99 and a 200 day moving average of $23.66. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.79. Cardlytics has a 52 week low of $9.80 and a 52 week high of $39.62.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.23. The firm had revenue of $48.73 million during the quarter, compared to the consensus estimate of $43.77 million. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The firm’s revenue was up 37.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.21) EPS. As a group, analysts forecast that Cardlytics will post -1.08 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on the company. JPMorgan Chase & Co. set a $43.00 target price on Cardlytics and gave the company a “buy” rating in a research report on Friday, August 9th. Bank of America reiterated a “buy” rating and issued a $32.00 price target (up from $22.00) on shares of Cardlytics in a report on Wednesday, July 24th. Raymond James boosted their price target on Cardlytics from $24.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Zacks Investment Research downgraded Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, ValuEngine downgraded Cardlytics from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $33.29.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Do equity income investments outperform growth and income investments?

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.